Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis

Boris Hügle*, Fabian Speth and Johannes-Peter Haas

Abstract

Background: Inflammatory bowel disease can develop in the context of some rheumatic diseases in childhood, including juvenile idiopathic arthritis (JIA). Inflammatory bowel disease (IBD) is frequently associated with other immune-mediated diseases; however, systemic onset JIA (sJIA) has not previously been connected to IBD. Treatment of sJIA has significantly changed in recent years, possibly causing changes in inflammatory patterns. Therefore, data from the German Center for Pediatric and Adolescent Rheumatology from 2010 until 2015 were analyzed by retrospective chart review.

Findings: Eighty-two patients with confirmed diagnosis of sJIA were found. Of these, three were identified with a diagnosis of IBD confirmed by colonoscopy (two cases of Crohn’s disease, one case of ulcerative colitis) 0.8–4.3 years after diagnosis. All three were treated with IL-1 antagonists (anakinra in two cases, canakinumab in one case) and were well controlled for sJIA symptoms at time of diagnosis of IBD.

Conclusions: IBD seems to be a rare, but possible complication of sJIA. Treatment with IL-1 antagonists might be a relevant factor for a switch in the clinical phenotype of the underlying inflammatory process.

Keywords: Systemic juvenile idiopathic arthritis, Inflammatory bowel disease, IL-1 Antagonists

Findings

Systemic-onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease characterized by increased levels of interleukin(IL)-1 and IL-6 [1]. Anakinra and canakinumab are both medications used successfully in sJIA, aiming to neutralize the effects of IL-1 [2, 3].

Inflammatory bowel diseases (IBD) are associated with several immune-mediated diseases, with almost a quarter of patients showing first symptoms during childhood or adolescence [4]. While unspecific mild bowel inflammation has been described in sJIA, IBD has not been observed as an extrarticular manifestation [5, 6].

We present three pediatric cases with confirmed diagnosis of sJIA who developed IBD diagnosed by histology and colonoscopy during treatment with IL-1 antagonists.

Patients and Methods

The database of the German Center for Pediatric and Adolescent Rheumatology was searched for all sJIA patients (n = 82) with a confirmed diagnosis of IBD from 2010 until 2015. Four patients were identified; one was excluded as histology showed only unspecific round-cell infiltrate. Chart survey was used to extract demographic data, date of diagnosis of sJIA and IBD, clinical and laboratory data and medications.

Case descriptions

Clinical and laboratory data of the cases at time of diagnosis of sJIA and of IBD are described in Tables 1 and 2, respectively. (Additional file 1: Table S1 and Additional file 2: Table S2).

Case I is a Caucasian male. He presented at age 14 years and 10 months with high quotidian fever with associated diffuse exanthema, splenomegaly, mild pericardial effusion and polyarthritis. Infectious workup showed elevated IgG and IgM antibodies against Parvovirus B19. He did not complain about abdominal symptoms and had a normal
bowel ultrasound except for splenomegaly. He received methylprednisolone pulse therapy and indomethacin and was started on anakinra, with rapid remission within 3 months.

After 11 months on anakinra he developed increasing abdominal pain and diarrhea. Stool cultures were negative. Colonoscopy showed ileitis and discontinuous inflammation in the ascending colon. Histology confirmed granulomatous inflammation. With a diagnosis of Crohn’s disease he was started on azathioprine and prednisolone, while anakinra was tapered. He presented 3 months later with fevers and markedly elevated inflammatory parameters.

Table 1 Demographics of the patients, clinical and laboratory data at time of diagnosis of sJIA, and time and dose of anti-IL-1 medication

| Patient | 1          | 2          | 3          |
|---------|------------|------------|------------|
| Gender  | m          | m          | f          |
| ANA/RF/HLA-B27 | neg/neg/neg | neg/neg/n.d. | neg/neg/neg |
| Age at diagnosis | 14.8       | 15.8       | 6.8        |
| ILAR criteria for subtype | Fever, typical rash, splenomegaly, pericardial effusion | Fever, rash, pericardial/pleural effusion, hepatomegaly | Fever, rash, pleural effusion, hepatomegaly splenomegaly |
| Affected joints | Polyarthritis | Polyarthritis | Elbows, hips, wrists |
| Leukocyte count | 9100/mm³ (4800–10000) | 9100/mm³ (4500–12500) | 16800/mm³ (4800–10000) |
| Platelet count | 294000/mm³ (150000–450000) | 208000/mm³ (154000–386000) | 575000/mm³ (150000–450000) |
| Ferritin | 2926 µg/l (30–400) | 32722 ng/ml (22–322) | 297–1197 µg/l (30–400) |
| C-reactive protein | 7.4 mg/dl (0.2–1.0) | 28.54 mg/dl (<0.3) | 3.36 mg/dl (0.2–1.0) |
| Bone marrow biopsy findings | Negative | MAS | - |
| Start of IL1-treatment, years after diagnosis | 0 years | 2.2 years | 0.3 years |
| IL-1 agents, initial dose | Anakinra, 1.3 mg/kg | Canakinumab, 1.8 mg/kg | Anakinra |

normal values in parentheses

neg negative, n.d. not done

Table 2 Colonoscopy findings, clinical and laboratory data at time of diagnosis of IBD of the patients

| Patient | 1          | 2          | 3          |
|---------|------------|------------|------------|
| Time between diagnoses of sJIA and IBD | 0.9 years | 4.4 years | 4.7 years |
| Time between start of Anti-IL1 agent and IBD | 0.9 years | 2.2 years | 4.4 years |
| Anti-IL1 agents, dosage | Anakinra, 1.3 mg/kg | Canakinumab, 1.8 mg/kg | Anakinra, 0.7 mg/kg |
| Other medications | None | Cyclosporin A | None |
| Colonoscopy, macroscopic findings | Active, ulcerous ileitis and colitis, consistent with Crohn’s disease | Active colitis from sigmoid to coecum, consistent with Crohn’s disease | Colitis in colon descendens, consistent with ulcerative colitis |
| Colonoscopy, microscopic findings | Granulomatous inflammation | Inflammatory infiltrate | Inflammatory infiltrate |
| Diarrhea | Present | Present | Present |
| Macroscopic blood in stool | Absent | Absent | Present |
| Ferritin | 138 ng/ml (9–80) | 154 ng/ml (30–400) | 10 ng/ml (30–400) |
| CRP | 12.1 mg/dl (<0.8) | 4.67 mg/dl (0.02–1.0) | 0.44 mg/dl (0.2–1.0) |
| Calprotectin/stool | Not available | 877 µg/g (<50) | 1264 µg/g (<50) |

normal values in parentheses
without diarrhea. After excluding systemic inflammation or infection, his colonoscopy was repeated and returned a result of highly active Crohn's disease. Treatment with infliximab and methotrexate was started, leading to rapid and ongoing remission 8 months later.

Case II is a Caucasian male, who presented at age 15 years and 10 months with fevers, arthritis and exanthema and developed polyarthritis, pericardial and pleural effusion within a few weeks. At that time, he had borderline positive IgM antibodies against Coxsackie virus, Adenovirus and Epstein-Barr virus. He was treated with NSAID and steroids, but developed two episodes of macrophage activation syndrome, with recurrence on cyclosporin after the first episode. Three months prior to the second episode, he was diagnosed with Influenza A. Twenty-three months after diagnosis he was started on anakinra after methylprednisolone which led to brief improvement. Three months later he presented with severe signs of systemic arthritis and elevated inflammatory parameters. Treatment with tocilizumab showed no improvement, but canakinumab – in addition to cyclosporine and low dose steroids – led to rapid and lasting remission over the next 2 years.

After 24 months on canakinumab he presented with fatigue, arthralgias without arthritis and elevated C-reactive protein, with diarrhea and weight loss. Increasing doses of canakinumab and prednisolone did not lead to improvement. Infectious work-up showed again borderline positive IgM antibodies against Coxsackie, but negative stool cultures. Colonoscopy showed active colitis extending from proximal sigmoid to the cecum with several, partly confluent ulcerations. The iliocecal valve was gaping, and the terminal ileum exhibited erythema and punch defects of the mucosal membrane. Duodenal biopsy showed edematous and coarse villi, with detachment of epithelium of the mucosal membrane. Duodenal biopsy showed edematous and coarse villi, with detachment of epithelium and mostly neutrophilic inflammatory infiltrate. Even without granuloma formation, this was interpreted as Crohn's disease, supported by positive antibodies against Saccharomyces cerevisiae (ASCA). Canakinumab was discontinued, and he was started on bunedoside and infliximab, which led to rapid remission, ongoing 18 months after diagnosis of IBD.

Case III is a Caucasian male of mixed German and Turkish origin. He presented at age 6 years and 10 months with fevers, arthritis, exanthema, pleural effusion and oligoarthritis. An extensive infectious workup showed no result. He was treated with indomethacin, steroids and methotrexate. He presented 4 months later with arthritis, fevers and elevated inflammatory parameters. Treatment with steroids and etanercept showed no effect after 3 doses, so he was switched to anakinra, leading to prompt improvement of clinical signs and laboratory parameters.

He entered long lasting remission, but started to develop mild abdominal symptoms after 3 years on anakinra and methotrexate. Methotrexate was discontinued 6 months later, and in the following months he showed increasing abdominal pain and blood in his stools. Stool cultures were negative. He received a colonoscopy 4 years after starting anakinra, which showed severe inflammation of the colon descendens consistent with ulcerative colitis, with histology showing edema of the lamina propria with inflammatory lymphocytic and neutrophilic infiltrate, and also focal inflammation in the crypt walls. He was continued on low dose anakinra (0.5 mg/kg) and started on mesalazin and azathioprine, with ongoing mild gastrointestinal complaints on last follow-up.

Discussion

Here we present three patients with confirmed diagnosis of sJIA who developed signs of IBD on treatment with anti-IL1 agents, either anakinra or canakinumab. All cases fulfilled ILAR criteria for sJIA at the time of diagnosis, and none had any clinical signs of IBD at that time. Although the age range in these patients falls well within the described spectrum, the majority of patients with sJIA initially present below the age of 5 years. All patients developed typical manifestations of Crohn's disease or ulcerative colitis, where monoclonal TNFα antibodies or DMARDs were required to gain disease control (for comparison, see Table 3). The one patient receiving low-dose anakinra in fact continued to have low grade abdominal symptoms, possibly indicating an ongoing pro-inflammatory effect of anti-IL1 medication.

Few reports exist of patients with sJIA developing IBD. Twenty-nine patients with various subtypes of JIA, including three with sJIA, have been linked to IBD on treatment with etanercept, and one on infliximab [7–9]. All three patients developed Crohn's disease between 5 and 12 years after diagnosis of sJIA on treatment with etanercept; all patients went into clinical remission after discontinuation of etanercept and treatment of IBD. A recent survey from the German biologics registry did find IBD in eleven of 3,071 patients with JIA, but none with sJIA [10]. Endoscopic studies on 27 JIA patients with gastrointestinal symptoms also found ulcerative colitis in five patients (19%), but none with sJIA [5]. Phenotypes of rheumatic diseases can evidently change over time, especially in childhood. sJIA changes from IL-1 driven acute febrile sJIA to IL-17 driven chronic active sJIA over time [1]. In endoscopic mucosal samples, IBD similarly exhibits a strong T_{17} phenotype in early lesions and switches to a T_{1} phenotype, with marked increase in IL-17A, and induction of IL-6 and IL-23; it can occur subsequent to different categories of JIA as well as spondyloarthropathies [11, 12]. IBD, especially Crohn's disease, is considered an NF-kB activation disorder as part of the spectrum of autoinflammatory diseases, where cross-overs have frequently been observed – a change of sJIA into an IBD phenotype therefore seems at least possible in theory [13]. In fact, a recent study of
mucosal biopsies in 33 JIA patients with gastrointestinal symptoms included eight with sJIA, with two patients with mild eosinophilic infiltration in the colon, and one 4 year old patient with active gastrointestinal inflammation [6].

All three patients were exposed to IL-1 antagonists when developing symptoms of IBD. IL-1 is known to be expressed at high levels in colonic biopsies from patients with IBD, supporting the hypothesis of a pro-inflammatory role. Animal models of colitis both in rabbits and rats improved with blockade of IL-1 [14]. However, recent mouse models show a differentiated role for IL-1α and IL-1β, where IL-1α, produced mainly by colonic epithelial cells, acts in an inflammatory fashion [15]. In comparison, IL-1β, produced mostly by myeloid cells, promotes healing and repair in colonic tissue; IL-1β deficient mice show more severe colitis with failure of repair mechanisms [16]. Anakinra blocks both IL-1α and IL-1β, but in the mouse model described, experimental specific IL-1α antibodies were significantly more efficacious in reducing severity of colitis compared to external IL-1 receptor antagonist (IL-1RA). Canakinumab by design specifically targets IL1-β, with no effect on IL-1α. Disturbance of the IL1-1α/β equilibrium by these medications might possibly create a pro-inflammatory environment in the colon, leading to IBD in selected cases. Patients with active IBD have in fact been shown to have increased levels of IL-1RA [17]. So far, no clinical trials have been reported for IL-1 antagonists in IBD, but one case of IBD worsening with anakinra treatment has been described [18]. One patient with sJIA in a randomized clinical trial for anakinra did also in fact develop Crohn’s disease [19].

Gastrointestinal symptoms in JIA are not uncommon, with several series describing results from gastrointestinal investigations [5, 6]. The majority of cases, including those with sJIA, show mild, nonspecific inflammation, frequently with a prominent eosinophilic infiltrate, with more severe inflammation in only a few cases. It is possible that the three cases presented here represent the extreme end of this spectrum. However, all three patients had ongoing, severe abdominal manifestations over several months while sJIA symptoms were well controlled. The three patients had extensive infectious work-up during diagnosis, which showed positive IgM antibodies for various pathogens, whose impact on the disease progression and change in phenotype is unclear.

This is a case series; therefore, any conclusions about an underlying pathological mechanism would be premature. The impact of medications on the development of IBD is unclear: the interval between IL-1 blocker treatment and IBD manifestations is highly variable, and it is possible that methotrexate withdrawal in case 3 lead to uncovering of a previously subclinical IBD. However, three cases of IBD in a single tertiary center cohort of 82 patients argues against mere coincidence.

In summary, this is the first report of sJIA patients developing IBD in temporal connection with IL-1 antagonist treatment. It is not clear if these cases are coincident, represent a change in patterns of inflammation of sJIA or are a consequence of treatment. Further efforts should aim at collecting more patients and elucidating the underlying disease processes.

### Additional files

**Additional file 1: Table S1.** Supplementary clinical and laboratory data for the patients at time of diagnosis of sJIA. (DOXC 23 kb)

**Additional file 2: Table S2.** Colonoscopy results of the 3 patients, translated and summarized from the German original. (DOXC 23 kb)

### Acknowledgements

Not applicable.
Funding
This study was not supported by any outside funding.

Availability of data and materials
The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
BH designed the study, performed the data collection and the analysis. FS and JPH participated in the analysis and helped draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Medical Faculty, Ludwig-Maximilians University Munich, Germany.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 28 September 2016 Accepted: 6 March 2017
Published online: 14 March 2017

References
1. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416–26.
2. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Corti E, Pardeo M, Mieltunen PM, Janow G, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55.
3. Ruperto N, Brunner HI, Quarter P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkovska-Sak L, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.
4. Kappelman MD, Galanko JA, Porter CO, Sandler RS. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child. 2011;96:1042–6.
5. Kokkonen J, Arvonen M, Vahasalo P, Karttunen TJ. Intestinal immune activation in juvenile idiopathic arthritis and connective tissue disease. Scand J Rheumatol. 2007;36:386–9.
6. Pichler J, Ong C, Shah N, Sebire N, Kiparrissi F, Borrelli O, Pilkington C, Elлавad M. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res. 2016.
7. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschch H, Armbrust W, Minden K, Prince FH, Kokke FT, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441–6.
8. Dall’occhio A, Canioni D, Ruemmele F, Duquesne A, Scaccese Jr, Bouvier R, Paraf F, Languepin J, Wouters CH, Guillot M, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010;49:1694–8.
9. Ruemmele FM, Prieur AM, Tallbotc C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr. 2004;39:203–6.
10. Barthel D, Gaense G, Kueter RM, Onken N, Minden K, Girschch HJ, Hospach A, Horneff G. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160–5.
11. Melants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, Maetens M, Joos R. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthopathy—a prospective study. J Rheumatol. 1993;20:1567–72.
12. Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G. Distinct profiles of effector cytokines mark the different phases of Crohn’s disease. PLoS One. 2013;8:e54562.
13. Masters SL, Simon A, Aksectijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of auto-inflammatory disease (*). Annu Rev Immunol. 2009;27:621–68.
14. Thomas TK, Will PC, Silvastava A, Wilson CL, Harbison M, Little J, Chesonis RS, Pignatelio M, Schmolde D, Symington J, et al. Evaluation of an interleukin-1 receptor antagonist in the rat acute acid-induced colitis model. Agents Actions. 1991;34:187–90.
15. Barnias G, Anseneau KO, Cominelli F. Cytokines and mucosal immunity. Curr Opin Gastroenterol. 2014;30:547–52.
16. Berdyski M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I, Aychev T, Dinarello CA, et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut. 2014;63:598–609.
17. Kuboyama S. Increased circulating levels of interleukin-1 receptor antagonist in patients with inflammatory bowel disease. Kurume Med J. 1998;45:33–7.
18. Carter JD, Valeniano I, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol. 2003;9:276–7.
19. Quartier P, Allantaz F, Cimaez R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJS trial). Ann Rheum Dis. 2011;70:747–54.